Elanco Animal Health Incorporated
ELAN
Rank in Stocks
#1821
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Share Price
$23.51
Last synced: 2026-10-19
Market Cap
$11.74B
Change (1 day)
-0.15%
Change (1 year)
8.22%
Country
US
Trade Elanco Animal Health Incorporated (ELAN)
Category
Healthcare
Earnings for Elanco Animal Health Incorporated (ELAN)
Earnings in Jun 2026 TTM: $-166.00M
According to Elanco Animal Health Incorporated latest financial reports the company's current earnings are $-166.00M. In 2023 the company made an earning of $-1.20B, a decrease compared to its 2022 earnings that were of $-72.00M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Elanco Animal Health Incorporated from 2015 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-166.00M | -134.02% |
| 2024 | $488.00M | -140.84% |
| 2023 | $-1.20B | 1,559.72% |
| 2022 | $-72.00M | -87.39% |
| 2021 | $-571.00M | -15.03% |
| 2020 | $-672.00M | -959.34% |
| 2019 | $78.20M | -31.46% |
| 2018 | $114.10M | -149.05% |
| 2017 | $-232.60M | 938.39% |
| 2016 | $-22.40M | -91.37% |
| 2015 | $-259.50M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -1,162.98% |
IN
|
